JP2010510254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510254A5 JP2010510254A5 JP2009537460A JP2009537460A JP2010510254A5 JP 2010510254 A5 JP2010510254 A5 JP 2010510254A5 JP 2009537460 A JP2009537460 A JP 2009537460A JP 2009537460 A JP2009537460 A JP 2009537460A JP 2010510254 A5 JP2010510254 A5 JP 2010510254A5
- Authority
- JP
- Japan
- Prior art keywords
- secretase inhibitor
- inositol
- scyllo
- inhibitor
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 43
- 229940121773 Secretase inhibitor Drugs 0.000 claims description 38
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 25
- 229960000367 inositol Drugs 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 14
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims description 12
- 230000003941 amyloidogenesis Effects 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000004220 aggregation Methods 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 230000012846 protein folding Effects 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 6
- 239000002439 beta secretase inhibitor Substances 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000002688 persistence Effects 0.000 claims description 6
- 230000004845 protein aggregation Effects 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 230000007082 Aβ accumulation Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 3
- 239000003540 gamma secretase inhibitor Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002195 synergetic effect Effects 0.000 claims description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000003977 synaptic function Effects 0.000 claims description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 3
- 208000037259 Amyloid Plaque Diseases 0.000 claims 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 claims 1
- NORCOJNIMIQRNC-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline-2-sulfonamide Chemical compound C1=CC=C2NC(S(=O)(=O)N)CCC2=C1 NORCOJNIMIQRNC-UHFFFAOYSA-N 0.000 claims 1
- ZZHJOZAJYVNDAS-UHFFFAOYSA-N 1,3-thiazole-2,4-dicarboxamide Chemical compound NC(=O)C1=CSC(C(N)=O)=N1 ZZHJOZAJYVNDAS-UHFFFAOYSA-N 0.000 claims 1
- LFWHFZJPXXOYNR-RQZCQDPDSA-N 2-[(3e)-6-fluoro-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]acetic acid Chemical compound C1=CC(SC)=CC=C1\C=C/1C2=CC=C(F)C=C2C(CC(O)=O)=C\1C LFWHFZJPXXOYNR-RQZCQDPDSA-N 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- 229940126077 BACE inhibitor Drugs 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 230000035508 accumulation Effects 0.000 claims 1
- DXZDEAJXVCLRLE-UHFFFAOYSA-N azepin-2-one Chemical compound O=C1C=CC=CC=N1 DXZDEAJXVCLRLE-UHFFFAOYSA-N 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- MURCDOXDAHPNRQ-PJRHAEEISA-N tert-butyl n-[(2s,3r,5s)-6-[[(2s)-1-[[(2s)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-benzyl-3-hydroxy-6-oxo-1-phenylhexan-2-yl]carbamate Chemical group C([C@@H]([C@H](O)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)CC=1C=CC=CC=1)NC(=O)OC(C)(C)C)C1=CC=CC=C1 MURCDOXDAHPNRQ-PJRHAEEISA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 6
- -1 cycloalkynyl Chemical group 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CTQJAETYIVEEFX-UHFFFAOYSA-N [N-]=[N+]=NN(N)N=[N+]=[N-] Chemical compound [N-]=[N+]=NN(N)N=[N+]=[N-] CTQJAETYIVEEFX-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- CDAISMWEOUEBRE-NIPYSYMMSA-N epi-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](O)[C@H]1O CDAISMWEOUEBRE-NIPYSYMMSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000005000 thioaryl group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86088406P | 2006-11-24 | 2006-11-24 | |
| PCT/CA2007/002118 WO2008061373A1 (en) | 2006-11-24 | 2007-11-22 | Combination treatments for alzheimer's disease and similar diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510254A JP2010510254A (ja) | 2010-04-02 |
| JP2010510254A5 true JP2010510254A5 (enExample) | 2012-01-12 |
Family
ID=39429352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537460A Pending JP2010510254A (ja) | 2006-11-24 | 2007-11-22 | アルツハイマー病および関連の神経変性疾患のための併用処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100292157A1 (enExample) |
| EP (1) | EP2091566A4 (enExample) |
| JP (1) | JP2010510254A (enExample) |
| CA (1) | CA2670405A1 (enExample) |
| WO (1) | WO2008061373A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US20100144891A1 (en) * | 2007-04-12 | 2010-06-10 | Mclaurin Joanne | Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| CN104869993B (zh) * | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| HK1223541A1 (zh) | 2013-10-22 | 2017-08-04 | The General Hospital Corporation | 色甘酸衍生物以及成像和治疗的相关方法 |
| GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
| RS61013B1 (sr) | 2014-10-24 | 2020-11-30 | Landos Biopharma Inc | Terapeutski preparati zasnovani na lantionin sintetazi c- sličnom proteinu-2 |
| WO2017095250A1 (en) * | 2015-11-30 | 2017-06-08 | Centro De Neurociências E Biologia Celular | Peptide inhibitors of bace1 for the treatment of neurological disorders |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア |
| KR20210070232A (ko) | 2017-07-20 | 2021-06-14 | 아즈테라피즈 인코포레이티드 | 크로몰린 나트륨 및 이부프로펜의 분말화된 제형 |
| EA202091325A1 (ru) | 2017-11-30 | 2020-08-28 | Лэндос Байофарма, Инк. | Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток |
| JP2021529771A (ja) | 2018-07-02 | 2021-11-04 | ザ ジェネラル ホスピタル コーポレイション | クロモリンナトリウムおよびα−ラクトースの粉末製剤 |
| US12383528B2 (en) | 2018-12-10 | 2025-08-12 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| JP7430852B2 (ja) | 2019-12-20 | 2024-02-14 | エヌイミューン バイオファーマ インコーポレイテッド | ランチオニンｃ様タンパク質２リガンド、それを用いて調製される細胞、およびそれを使用する療法 |
| IL297023A (en) | 2020-04-06 | 2022-12-01 | Massachusetts Gen Hospital | Methods for treating inflammatory conditions caused by the corona virus |
| JP2025530190A (ja) * | 2022-09-07 | 2025-09-11 | エアジェン ファーマ リミテッド | アルツハイマー病治療のための免疫療法薬とｓｃｙｌｌｏ－イノシトールとの組み合わせ |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
| US4952396A (en) * | 1986-11-19 | 1990-08-28 | Linus Pauling Institute Of Science & Medicine | Method of using phytic acid for inhibiting tumor growth |
| US4758430A (en) * | 1987-01-21 | 1988-07-19 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| SE8904355D0 (sv) * | 1989-12-21 | 1989-12-21 | Perstorp Ab | Medicament |
| US5217959A (en) * | 1990-09-06 | 1993-06-08 | Robert Sabin | Method of treating multiple sclerosis with phytic acid |
| US5112814A (en) * | 1990-10-24 | 1992-05-12 | Robert Sabin | Method of treatment of Parkinson's disease using phytic acid |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| SE9102068L (sv) * | 1991-07-03 | 1993-01-04 | Perstorp Ab | Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav |
| SE9200547L (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
| EP1225175B1 (en) * | 1992-10-05 | 2005-03-30 | Virginia Tech Intellectual Properties, Inc. | Intermediate for the synthesis of D-chiro-3-inosose and (+)-D-chiro-inositol |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| ES2202305T3 (es) * | 1993-04-05 | 2004-04-01 | Aveve N.V. | Hidrolisis de fitina y composicion de enzimas que tienen actividad hidrolizante de fitato. |
| WO1995004711A1 (en) * | 1993-08-11 | 1995-02-16 | Hokko Chemical Industry Co., Ltd. | Process for producing d-chiro-inositol |
| SE502574C2 (sv) * | 1994-01-25 | 1995-11-13 | Perstorp Ab | En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6232486B1 (en) * | 1996-06-11 | 2001-05-15 | Nutrimed Biotech | Molecular probes and modulators for PI-PLC and PI 3-kinase |
| US5880099A (en) * | 1996-09-20 | 1999-03-09 | The Regents Of The University Of California | Inositol polyphosphates and methods of using same |
| US5977078A (en) * | 1996-09-20 | 1999-11-02 | The Regents Of The Univesity Of California | Inositol polyphosphate derivatives and methods of using same |
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| US6153603A (en) * | 1997-06-27 | 2000-11-28 | Perstorp Ab | Method of treating angiogenesis in tumor tissue |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| US6818430B1 (en) * | 1999-06-07 | 2004-11-16 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol |
| US6329256B1 (en) * | 1999-09-24 | 2001-12-11 | Advanced Micro Devices, Inc. | Self-aligned damascene gate formation with low gate resistance |
| DE60032781D1 (de) * | 1999-10-18 | 2007-02-15 | Muscletech Res And Dev Inc | Nahrungsmittelzusatz zur zunahme der fettarmen körpermasse und kraft |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| DE10031955A1 (de) * | 2000-06-30 | 2002-01-17 | Deutsches Krebsforsch | Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel |
| CA2437561A1 (en) * | 2001-02-06 | 2002-08-15 | Qlt Inc. | Use of additional photodynamic therapy in the treatment of choroidal neovasculature |
| US8034803B2 (en) * | 2001-02-06 | 2011-10-11 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| WO2003007944A1 (en) * | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| ES2341964T3 (es) * | 2003-10-14 | 2010-06-30 | Hokko Chemical Industry Co., Ltd. | Proceso para producir escilo-inositol. |
| US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| AU2005306531B2 (en) * | 2004-11-17 | 2012-02-23 | Joanne Mclaurin | Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
| US20070111970A1 (en) * | 2005-10-13 | 2007-05-17 | Antonio Cruz | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence |
| CA2579188A1 (en) * | 2006-02-17 | 2007-08-17 | Joanne Mclaurin | Treatment of amyloid-related diseases |
| EP1996175A4 (en) * | 2006-03-09 | 2009-06-10 | Waratah Pharmaceuticals Inc | CYCLOHEXAN POLYALKOHOL FORMULATION FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS |
| US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
-
2007
- 2007-11-22 EP EP07845583A patent/EP2091566A4/en not_active Withdrawn
- 2007-11-22 CA CA002670405A patent/CA2670405A1/en not_active Abandoned
- 2007-11-22 US US12/445,164 patent/US20100292157A1/en not_active Abandoned
- 2007-11-22 JP JP2009537460A patent/JP2010510254A/ja active Pending
- 2007-11-22 WO PCT/CA2007/002118 patent/WO2008061373A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510254A5 (enExample) | ||
| CA2994987C (en) | Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex | |
| AU2014251087B2 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| US20240066042A1 (en) | Use of derivatives containing c-o-p bonds in patients with kidney failure | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| WO2019199776A1 (en) | Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders | |
| JP2018521092A5 (enExample) | ||
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| CA2670405A1 (en) | Combination treatments for alzheimer's disease and related neurodegenerative diseases | |
| JP2018536641A5 (enExample) | ||
| JP2011509286A (ja) | 精神神経系障害の治療のための、医薬組成物並びにｄ−アミノ酸及び抗酸化物を利用する方法 | |
| JP2011140521A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2725626C2 (ru) | Применение производных, содержащих связи с-о-р, у пациентов с почечной недостаточностью | |
| US20250302853A1 (en) | Ip and ip analogs dosage regimens for the treatment of ectopic calcifications | |
| IL265761B2 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| RU2494736C2 (ru) | Комбинация, включающая паклитаксел, для лечения рака яичников | |
| TW202028182A (zh) | 用於癌症治療之免疫調節之組合 | |
| BRPI0418973A (pt) | composições de risedronato e seus métodos de uso | |
| JP6878596B2 (ja) | Ｆｘｒアゴニストの組合せ | |
| JP2014534229A5 (enExample) | ||
| CA3053441C (en) | COMBINATION OF N-ACETYLCYSTEINE AND COLISTIN INTENDED FOR USE IN BACTERIAL INFECTIONS | |
| US20210023028A1 (en) | Use of histone acetyltransferase inhibitor amidoximes for histone acetyltransferase malfunction related pathology | |
| JP2021525750A (ja) | トロピフェクサーとセニクリビロックとを含む組合せ | |
| RU2500415C2 (ru) | Комбинированный лекарственный препарат |